Aehr Test Systems (NASDAQ:AEHR) saw its stock decline sharply on Friday, closing at $76.32—a drop of 13.8%—bringing the weekly loss to 5.8%. The selloff came despite the company revealing a robust effective backlog of $100.6 million, which represents between 67% and 77% of its projected revenue for fiscal 2027.
Backlog Provides Strong Visibility
According to management, the effective backlog covers 77% of the lower end of the revenue guidance range and 67% of the upper bound. The gap between the backlog and the guidance stands between $29.4 million and $49.4 million, underscoring the importance of converting orders into shipments. Chief Executive Gayn Erickson highlighted "substantial visibility" for revenue through fiscal 2027, with the company targeting $130 million to $150 million in sales. Aehr also projects non-GAAP net income at 18% to 22% of revenue.
Market Cap and Valuation
At Friday's close, Aehr's market capitalization reached $2.34 billion, translating to a multiple of 15.6 to 18.0 times projected sales. This valuation places significant emphasis on the company's ability to execute on its shipment schedule, secure customer acceptance, and convert its order book into recognized revenue.
Quarterly Performance
In the fourth quarter, revenue surged 33% year-over-year to $18.8 million. Bookings hit a record $60.7 million, resulting in an impressive book-to-bill ratio of 3.2. However, full-year revenue declined by 15% to $50 million, reflecting a challenging prior period.
Analyst Reaction
Lake Street Capital Markets responded to the outlook by raising its price target on Aehr from $56 to $110, maintaining a Buy rating. The firm described Aehr's forecast as "well above" its previous projection of $84 million.
Stock Movement and Sector Context
Aehr shares had surged 27.9% to $98.91 on Tuesday before reversing course over the next three sessions, with the attempted recovery fading. The stock ended Friday 24.6% below its Wednesday high of $101.22. The broader semiconductor-test equipment sector also faced headwinds: Teradyne (NASDAQ:TER) dropped 6.4% on Friday but gained 8.5% for the week, while Cohu (NASDAQ:COHU) fell 7.0% on Friday and slipped 1.0% week-over-week. The Nasdaq Composite slipped 0.6% on Friday, recording a weekly loss of 2.1%, meaning Aehr underperformed the index by roughly 3.7 percentage points over the past five sessions.
Upcoming Earnings Reports
Investors will be watching the test equipment sector closely this week. Teradyne is set to report its second-quarter earnings on Tuesday after market close, with a conference call on Wednesday at 8:30 a.m. EDT. Cohu will follow on Thursday at 4 p.m. EDT, with its call half an hour later. Market participants are expected to monitor AI-linked test demand, order schedules, and customer spending patterns. Notably, neither competitor serves as a direct proxy for Aehr.
Risk Factors
Customer concentration remains a significant risk. The most recent filing shows that a single customer accounted for 42.1% of revenue in the fiscal third quarter. Any delays or cancellations from this customer could shift sales to different quarters. While Aehr's backlog has reduced demand uncertainty, it has not eliminated conversion or valuation risks. Fiscal 2026 revenue declined by 15%, adding to the cautious backdrop.
